Seung Hyun Kim
Yonsei University · 医学
研究室紹介
Professor Seung Hyun Kim's research lab focuses on regenerative medicine and neuroimmunology, with a primary emphasis on developing stem cell-based therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The lab investigates the mechanisms underlying mesenchymal stromal cell (MSC) therapy, particularly the role of immunomodulatory factors like transforming growth factor-β (TGF-β) in regulating microglial function and neuroinflammation. A key research direction involves identifying predictive biomarkers—such as TGF-β levels in MSCs—to improve patient selection and treatment outcomes in autologous MSC transplantation. The lab also explores disease-modifying potential of existing drugs like donepezil in Alzheimer’s disease through neuroprotective mechanisms beyond cholinesterase inhibition.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15UNLABELLED: Stem cell therapy is an emerging alternative therapeutic or disease-modifying strategy for amyotrophic lateral sclerosis (ALS). The aim of this open-label phase I clinical trial was to evaluate the safety of two repeated intrathecal injections of autologous bone marrow (BM)-derived mesenchymal stromal cells (MSCs) in ALS patients. Eight patients with definite or probable ALS were enrolled. After a 3-month lead-in period, autologous MSCs were isolated two times from the BM at an inter
OBJECTIVE: To assess the safety and efficacy of 2 repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in amyotrophic lateral sclerosis (ALS). METHODS: In a phase 2 randomized controlled trial (NCT01363401), 64 participants with ALS were randomly assigned treatments (1:1) of riluzole alone (control group, n = 31) or combined with 2 BM-MSC injections (MSC group, n = 33). Safety was assessed based on the occurrence of adverse events. The primary effica
: The regulation of microglial cell phenotype is a potential therapeutic intervention in neurodegenerative disease. Previously, we reported that transforming growth factor-β (TGF-β) levels in mesenchymal stromal cells (MSCs) could be used as potential biological markers to predict the effectiveness of autologous MSC therapy in patients with amyotrophic lateral sclerosis. However, the underlying mechanism of TGF-β in MSCs was not fully elucidated in determining the functional properties of microg
Alzheimer's disease (AD) is associated with neurodegenerative changes resulting clinically in progressive cognitive and functional deficits. The only therapies are the cholinesterase inhibitors donepezil, galantamine and rivastigmine and the N-methyl-D-aspartate-receptor antagonist memantine. Donepezil acts primarily on the cholinergic system as a symptomatic treatment, but it also has potential for disease modification and may reduce the rate of progression of AD. This review explores the poten
mutations can contribute to ALS pathogenesis through toxic gain-of-function mechanisms involving abnormal protein aggregation.